Desvenlafaxine Tablet, Extended Release
Product Images NDC 63629-7559

Product Visual Gallery

This gallery contains 7 technical images submitted to the FDA as part of the official labeling for Desvenlafaxine (NDC 63629-7559). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Bryant Ranch Prepack, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Figure 1 (Desvenlafaxine Figure1)

This is a report of the geometric mean ratio (with respective percentage confidence interval) for the maximum concentration (Cmax) and area under the concentration-time curve (AUC) of a drug in individuals with varying degrees of renal or hepatic impairment, as compared to individuals with normal organ function. Additionally, the report provides information on how the drug affects different populations (such as females and individuals over 65 years old). The drug's effects are given on a relative scale compared to a reference population. The drug is not named, and the report does not provide information on the drug's indications or dosage.*

FDA Label Image

Figure 2 (Desvenlafaxine Figure2)

This appears to be a table showing changes in Cmax (maximum concentration in blood plasma) and AUC (area under the concentration-time curve) for ketoconazole, a CYP3A4 inhibitor, compared to a reference, represented by geometric mean ratios with 30% confidence intervals. However, without context or further information, it is difficult to understand the significance of these changes.*

FDA Label Image

Figure 3 (Desvenlafaxine Figure3)

FDA Label Image

Figure 4 (Desvenlafaxine Image4)

FDA Label Image

Figure 5 (Desvenlafaxine Image5)

The text describes a chart or graph showing the estimated proportion of patients with relapse over time for a specific medication (Desvenlafaxine Extended-Release Tablets) compared to a placebo. The chart measures the time to relapse in days from randomization, with percentage values ranging from 20% to 50%. There are also labeled axes showing the time to relapse in days and the percentage of patients with relapse.*

FDA Label Image

Structure (Desvenlafaxine Structure1)

FDA Label Image

Label (Lbl636297559)

This text contains information about a pharmaceutical product, "Pristig 100mg Tablet," and its packaging. The name of the company that packaged it is "Bryant Ranck Prepack." Additionally, the text includes the drug's expiration date, NDC number, and manufacturer's address. There are also storage instructions and a warning to keep drugs out of reach of children.*

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.